IJC Heart & Vasculature,
Journal Year:
2024,
Volume and Issue:
54, P. 101482 - 101482
Published: Aug. 2, 2024
Cardiovascular
complications
of
COVID-19
are
numerous
and
aspects
this
phenomenon
not
well
known.
The
main
objective
manuscript
is
a
systematic
review
the
acute
chronic
cardiovascular
secondary
to
COVID-19.
A
literature
through
Medline
via
PubMed
was
conducted
(2020-2024).
There
plethora
effects
on
heart
in
setting.
Here
we
discuss
pathophysiology,
myocardial
infarctions,
failure,
Takotsubo
Cardiomyopathy,
injury,
myocarditis
arrhythmias
that
caused
by
Additionally,
these
injuries
can
linger
may
be
an
underlying
cause
some
Long
COVID
symptoms.
life-threatening.
affect
health.
Microclotting
induced
SARS-CoV-2
infection
could
therapeutic
target
for
Covid.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Feb. 28, 2024
The
COVID-19
pandemic
continues
to
cause
severe
global
disruption,
resulting
in
significant
excess
mortality,
overwhelming
healthcare
systems,
and
imposing
substantial
social
economic
burdens
on
nations.
While
most
of
the
attention
therapeutic
efforts
have
concentrated
acute
phase
disease,
a
notable
proportion
survivors
experience
persistent
symptoms
post-infection
clearance.
This
diverse
set
symptoms,
loosely
categorized
as
long
COVID,
presents
potential
additional
public
health
crisis.
It
is
estimated
that
1
5
exhibit
clinical
manifestations
consistent
with
COVID.
Despite
this
prevalence,
mechanisms
pathophysiology
COVID
remain
poorly
understood.
Alarmingly,
evidence
suggests
cases
within
condition
develop
debilitating
or
disabling
symptoms.
Hence,
urgent
priority
should
be
given
further
studies
equip
systems
for
its
management.
review
provides
an
overview
available
information
emerging
condition,
focusing
affected
individuals’
epidemiology,
pathophysiological
mechanisms,
immunological
inflammatory
profiles.
Diagnostics,
Journal Year:
2024,
Volume and Issue:
14(7), P. 711 - 711
Published: March 28, 2024
Four
years
post-pandemic,
SARS-CoV-2
continues
to
affect
many
lives
across
the
globe.
An
estimated
65
million
people
suffer
from
long
COVID,
a
term
used
encapsulate
post-acute
sequelae
of
infections
that
multiple
organ
systems.
Known
symptoms
include
chronic
fatigue
syndrome,
brain
fog,
cardiovascular
issues,
autoimmunity,
dysautonomia,
and
clotting
due
inflammation.
Herein,
we
review
COVID
symptoms,
proposed
theories
behind
pathology,
diagnostics,
treatments,
clinical
trials
underway
explore
treatments
for
viral
persistence,
autonomic
cognitive
dysfunctions,
sleep
disturbances,
fatigue,
exercise
intolerance.
Viruses,
Journal Year:
2024,
Volume and Issue:
16(7), P. 1060 - 1060
Published: June 30, 2024
Since
the
emergence
of
SARS-CoV-2
virus
in
2019,
nearly
700
million
COVID-19
cases
and
7
deaths
have
been
reported
globally.
Despite
most
individuals
recovering
within
four
weeks,
Center
for
Disease
Control
(CDC)
estimates
that
7.5%
to
41%
develop
post-acute
infection
syndrome
(PAIS),
known
as
'Long
COVID'.
This
review
provides
current
statistics
on
Long
COVID's
prevalence,
explores
hypotheses
concerning
epidemiological
factors,
such
age,
gender,
comorbidities,
initial
severity,
vaccine
interactions,
delves
into
potential
mechanisms,
including
immune
responses,
viral
persistence,
gut
dysbiosis.
Moreover,
we
conclude
women,
advanced
non-vaccination,
low
socioeconomic
status
all
appear
be
risk
factors.
The
reasons
these
differences
are
still
not
fully
understood
likely
involve
a
complex
relationship
between
social,
genetic,
hormonal,
other
Furthermore,
with
seem
more
endure
economic
hardship
due
persistent
symptoms.
In
summary,
our
findings
further
illustrate
multifaceted
nature
COVID
underscore
importance
understanding
factors
mechanisms
needed
effective
therapeutic
strategies
interventions.
Nature Communications,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Feb. 13, 2025
The
ever-evolving
SARS-CoV-2
variants
necessitate
the
development
of
additional
oral
antivirals.
This
study
presents
systematic
design
quinoline-containing
papain-like
protease
(PLpro)
inhibitors
as
potential
antiviral
drug
candidates.
By
leveraging
recently
discovered
Val70Ub
binding
site
in
PLpro,
we
designed
a
series
quinoline
analogs
demonstrating
potent
PLpro
inhibition
and
activity.
Notably,
X-ray
crystal
structures
6
lead
compounds
reveal
that
2-aryl
substitution
can
occupy
either
expected
or
BL2
groove
flipped
orientation.
vivo
Jun13296
exhibits
favorable
pharmacokinetic
properties
against
nirmatrelvir-resistant
mutants.
In
mouse
model
infection,
treatment
with
significantly
improves
survival,
reduces
body
weight
loss
lung
viral
titers,
prevents
tissue
damage.
These
results
underscore
promising
candidates,
instilling
hope
for
future
treatment.
inhibitor,
Jun13296,
displays
efficacy
infection
inhibits
mutants,
rendering
it
candidate.
iScience,
Journal Year:
2023,
Volume and Issue:
26(8), P. 107280 - 107280
Published: July 4, 2023
Long-term
T
cell
dysregulation
has
been
reported
following
COVID-19
disease.
Prolonged
activation
is
associated
with
disease
severity
and
may
be
implicated
in
producing
long-covid
symptoms.
Here,
we
assess
the
role
of
extracellular
vesicles
(EV)
regulating
function
over
several
weeks
post
We
find
that
alterations
cellular
origin
protein
content
EV
convalescence
are
linked
to
initial
severity.
demonstrate
convalescent
donor-derived
can
alter
metabolic
rewiring
CD4
CD8
cells.
Of
note,
mild,
but
not
severe
disease,
show
distinctly
immune-suppressive
properties,
reducing
effector
cytokine
production
glucose
metabolism.
Mechanistically
our
data
indicate
involvement
EV-surface
ICAM-1
facilitating
EV-T
interaction.
Our
circulatory
phenotypically
functionally
altered
acute
infection,
suggesting
a
for
as
long-term
immune
modulators.
